I've been eagerly awaiting the lifting of ASCO's embargo on announcing accepted presentations. Well, the program has been released, including the abstract titles and presenters' names. I am so pleased to announce we're set to make a memorable showing at ASCO's annual meeting this June – with a record number of abstracts (41) and a plenary spotlight for the results of our S1826 trial in Hodgkin lymphoma. Now, all that remains is for you to read Front Line and attend the sessions, to learn about the actual trial data.

The list ASCO released this week includes 30 SWOG-led abstracts, plus another 11 with significant SWOG representation/input (here’s the full list).

Here are the five SWOG oral presentations you’ll want to mark on your calendar, starting with the plenary talk. It’s a nice variety including a variety of effective treatments using different modalities, a discussion of toxicity, and even a presentation by one of our leading statisticians.

  • “SWOG S1826, a Randomized Study of Nivolumab(N)-AVD versus Brentuximab Vedotin(BV)-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL)”
    Presenter: Alex Herrera, MD
  • “SWOG S1011 - A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer”
    Presenter: Seth P. Lerner, MD
  • “Change in RECIST Tumor Size Correlates Linearly with Survival in Patients Treated with Checkpoint Inhibitor Therapy (SWOG S1609)”
    Presenter: Megan Othus, PhD
  • “Chemotherapy Induced Peripheral Neuropathy (CIPN) due to Paclitaxel versus Docetaxel in Patients with Early-Stage Breast Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481)”
    Presenter: Meghna Trivedi, MD, MS
  • “SWOG S1929: Phase II Randomized Study of Maintenance Atezolizumab (A) Versus Atezolizumab + Talazoparib (AT) in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)”
    Presenter: Nagla Abdel Karim, MD

Those five oral presentations will be complemented by 20 other SWOG-led abstracts presented in poster sessions (this list is ordered by trial number). Again, the variety is quite breath-taking:

  • “Comparing the Prognostic and Predictive Utility of Serum Thymidine Kinase 1 and CA 15-3 in Patients with Hormone Receptor Positive Metastatic Breast Cancer Starting First-Line Endocrine Therapy in SWOG S0226”
    Presenter: Erin Cobain, MD
  • “Adjusted Indirect Treatment Comparison of Progression-Free Survival (PFS) Associated with DRd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data”
    Presenter: Brian Durie, MD
  • “Adjuvant Everolimus in Patients (Pts) with Localized Non-clear Cell Renal Cell Carcinoma (RCC): Subgroup Analysis from the EVEREST Trial (SWOG S0931)”
    Presenter: Shuchi Gulati, MD, MS
  • “Baseline Circulating Tumor Cell (CTC) Count as a Prognostic Marker of Overall Survival (OS) in Metastatic Castrate Sensitive Prostate Cancer (mCSPC): Results from SWOG S1216, a Phase III Randomized Trial of Androgen Deprivation Plus Orteronel (CYP17 Inhibitor) or Bicalutamide”
    Presenter: Amir Goldkorn, MD
  • “Bone Biomarkers and Subsequent Survival in Men with Bone-Metastatic Hormone Sensitive Prostate Cancer (HSPC): Results from the Phase III SWOG S1216 Trial of Androgen Deprivation +/- Orteronel”
    Presenter: Primo N. Lara, MD
  • “Prostate-Specific Antigen at 3 & 7 months (PSA-3mo, PSA-7mo) Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated with Androgen Deprivation With or Without Orteronel (SWOG S1216)”
    Presenter: Mamta Parikh, MD, MS
  • “Outcomes of African American (AA) versus Caucasian (CA) Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated with Androgen Deprivation Therapy (ADT) with or without Orteronel (O): Analysis of Patient-Level Data from the SWOG-1216 Phase 3 Trial”
    Presenter: Nicolas Sayegh, MD
  • “Pathologic Concordance Rate and Outcomes by Histologic Subtype in Advanced Papillary Renal Cell (pRCC) Carcinoma: an Analysis from the SWOG S1500 (PAPMET) Trial”
    Presenter: Abhishek Tripathi, MD
  • “Chemotherapy Dose Density is Prognostic for Patients with Resectable Pancreas Cancer: A Secondary Analysis of SWOG S1505”
    Presenter: Sameer Patel, MD
  • “A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Vulvar Cancers”
    Presenter: Young Kwang Chae, MD, MPH, MBA
  • “A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Desmoid Tumors (Cohort 27)”
    Presenter: Young Kwang Chae, MD, MPH, MBA
  • “HERCULES: A Prostate Cancer (PC) Sequencing Panel for Parallel Analysis of Circulating Tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs) (SWOG S1802)”
    Presenter: Daniel Bsteh, PhD
  • “ECOG-ACRIN LUNG-MAP S1900E Substudy (NCT04625647): A Phase II Study of Sotorasib in Participants (Pts) With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous (Non-sq) Non-Small Cell Lung Cancer (NSCLC)”
    Presenter: Sukhmani Padda, MD
  • “A Phase III Randomized Trial of Eribulin (E) with or without Gemcitabine vs Standard of Care (SOC) for Metastatic Urothelial Carcinoma (UC) Refractory to or Ineligible for PD/PDL1 Antibody (Ab): SWOG S1937”
    Presenter: Sarmad Sadeghi, MD, PhD
  • “A Randomized Phase 2 Trial of Encorafenib + Binimetinib +  Nivolumab vs Ipilimumab + Nivolumab in BRAFV600-Mutant Melanoma Brain Metastases: SWOG S2000 (NCT# 04511013)”
    Presenter: Zeynep Eroglu, MD
  • “Randomized Phase II Trial of Olaparib + Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 (gBRCA1/2+) Mutations: SWOG S2001 NCT04548752”
    Presenter: Vincent Chung, MD
  • “The Effect of ctDNA Tumor Fraction (TF) on Overall Survival and Concordance between Tissue Genomics and ctDNA in Lung-MAP”
    Presenter: Phillip C. Mack, PhD
  • “Association of Baseline Measures of Socioeconomic Deprivation and Healthcare Utilization in Patients Enrolled in SWOG Cancer Clinical Trials”
    Presenter: Dawn Hershman, MD, MS
  • “SWOG S1823/CCTG GCC1 - Translational Observational Investigational Study of the Liquid Biomarker microRNA 371a-3p in Newly Diagnosed Germ Cell Tumours - Real-World Trial Design, Rapid Accrual, and Robust Secondary Use of Data Opportunities”
    Presenter: Antoine Morin Coulombe, MD
  • "Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials"
    Presenter: Joseph Unger, PhD

SWOG-led work accepted for ASCO includes an additional five publication-only abstracts, and SWOG researchers are contributors to 11 abstracts led by other groups.

If you can’t make it to Chicago for the show, watch this space for a date and time for our next “Best of SWOG at ASCO” webinar, which we’ll schedule for later in June.

The run-up to ASCO, not to mention the meeting itself, is always an exciting time. With the wealth of SWOG work to be presented, and expectations of a fabulous plenary presentation, this will be a June to remember!

Other Recent Stories

ASH 2023: S1318 benefit for older patients with Ph+ ALL
Dec 9, 2023
Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL